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Dear Prof. Lisanti, Editor-in-Chief, 
 thank you very much for the opportunity to submit a second revised version of the 
paper 'Autophagic degradation contributes to muscle wasting in cancer cachexia'. The 
paper has been modified according to the reviewer's suggestions, including the 
experiments on differentiated myotubes (last point raised by the reviewer), despite these 
were not required in the first revision. The data obtained by treating C2C12 myotubes with 
low TNFα concentrations (5 ng/ml), as well as those obtained by injecting the cytokine in 
the skeletal muscle of intact animals, have now been provided. Just a comment, in this 
regard: we are asked to expose C2C12 cultures to 'physiological' concentrations of TNFα, 
and, on the other side, to verify that this cytokine induces muscle autophagy in vivo. 
However, all the possible ways to test TNFα effects in vivo, including those suggested by 
the reviewer, require (Moresi V. et al., PLoS ONE 4:e5570, 2009), or result in (Oliff A. et 
al., Cell, 50:555-563,1987; Coletti D. et al., Genesis, 43:120-128, 2005) high, markedly 
supraphysiological concentrations of the cytokine, that will very likely affect the whole 
organism and not just the treated muscle. As an example, the study by Coletti and 
coworkers demonstrates that TNFα gene transfer into the skeletal muscle induces 
systemic cachexia. In conclusion, with the due respect, we wonder about the physiological 
significance of the results obtained from such a study, and this was precisely the reason 
that lead us to discard the execution of the experiment during the first revision.   
 We really hope that in the present version the paper would become suitable for 
publication in The American Journal of Pathology. 
 
Best regards. 
Paola Costelli 
 
Point-by-point reply 
• a more accurate attempt to define the novelty of the present study in comparison 
with the data already available in the literature has been performed. Previous 
studies reporting data pertinent to the activation of autophagy in the model systems 
used in the present paper have been cited in the Introduction, taking care to 
underline the differences in terms of both approaches and results (page 4, lines 10-
25) and not only in the Discussion as in the previous revised version; 
• the experiments on C2C12 cultures have been repeated by using TNFα 5 ng/ml, in 
the presence or in the absence of bafilomycin A in order to assess also the 
  
'autophagic flux'. The data are reported in Figure S4B and in the Result section 
(page 12, line 28 – page 13, line 5). Such experiments have been performed on 
fully differentiated myotubes (6 days after switch to differentiation medium), as 
requested by the reviewer, although this point was not raised in the first revision; 
• an in vivo experiment has been performed to investigate if TNFα directly induces 
autophagy in the skeletal muscle. According to the reviewer's suggestion, we 
injected the cytokine in the gastrocnemius muscle of healthy mice. The results are 
shown in Figure S5 and discussed in the text (page 13, lines 14-19). TNFα 
concentration (40 µg/kg body weight) has been selected according to the data 
available in the literature (Langen et al., FASEB J, 18:227-237, 2004). Untreated 
mice have been used as controls, in order to avoid biases due to the probable 
systemic effects of intramuscular TNFα injection. 
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ABSTRACT 1 
Muscle protein wasting in cancer cachexia is a critical problem. The underlying mechanisms 2 
are still unclear, although the ubiquitin-proteasome system has been involved in the degradation 3 
of bulk myofibrillar proteins. The present work has been aimed to investigate if also autophagic 4 
degradation plays a role in the onset of muscle depletion in cancer-bearing animals as well as in 5 
glucocorticoid-induced atrophy and sarcopenia of aging. The results show that autophagy is 6 
induced in muscle in three different models of cancer cachexia as well as in glucocorticoid-treated 7 
mice. By contrast, autophagic degradation in the muscle of sarcopenic animals is impaired, but can 8 
be reactivated by calorie restriction. These results further demonstrate that different mechanisms 9 
are involved in pathological muscle wasting, and that autophagy, either excessive or defective, 10 
contributes to the complicated network that leads to muscle atrophy. In this regard, particularly 11 
intriguing is the observation that in both cancer hosts and TNFα-treated C2C12 myotubes insulin 12 
can only partially blunt autophagy induction. This would suggest that autophagy is triggered 13 
through mechanisms that cannot be circumvented by using classical up-stream modulators, 14 
prompting to identify more effective approaches to target this proteolytic system. 15 
 16 
17 
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INTRODUCTION 1 
Cancer cachexia is a multifactorial syndrome characterized by anorexia, weight loss and 2 
muscle wasting that significantly impairs patients' quality of life and survival, also reducing their 3 
tolerance to anti-neoplastic treatments. Despite the relevance of cachexia to patient outcome, 4 
however, effective cachexia treatments are still lacking, and only recently tumor-induced wasting 5 
is becoming to be considered as a prognostic tool 1. 6 
The mechanisms underlying muscle wasting in cancer cachexia are still unclear, although 7 
experimental and clinical studies have shown that hyperactivation of the ubiquitin-proteasome-8 
dependent proteolytic system plays a critical role 2, 3. In this regard, however, in the last few years 9 
the involvement of autophagic-lysosomal proteolysis has also been proposed. The lysosomal 10 
degradative system contributes to different cellular processes, such as degradation of cytoplasmic 11 
proteins and organelles,  limited cleavage or extensive degradation of various substrates, 12 
trafficking and recycling of molecules among internal organelles to and from the exterior of the 13 
cell, post-translational maturation of secretory products and storage of undigested material 4. 14 
Autophagy is the major process for degradation of cellular constituents, its rate being enhanced 15 
under stress conditions leading to organelle damage or under marked nutrients restriction 16 
(starvation), in order to recycle biomolecules for the synthesis of essential constituents 5.  In such 17 
conditions, autophagy has been shown to operate bulk proteolysis in most visceral tissues, such as 18 
the liver 6, while its role in the skeletal muscle has been emerging only during the last years. In this 19 
regard, few years ago a study reported for the first time that starvation-induced autophagy also 20 
occurs in the skeletal muscle 7, and  quite recently autophagy has been shown to contribute to 21 
starvation-induced muscle atrophy, with a mechanism involving TNFα receptor-associated factor 22 
(TRAF)6/Fn14 signaling 8. An altered lysosomal function has also been reported in several 23 
myopathies 9 and, more recently, autophagy-related genes (ATGs) have been shown to be  24 
induced in muscle by denervation or fasting, through a FoxO3-dependent mechanism 10. In this 25 
regard, FoxO3 has been proposed to regulate both autophagy and proteasome-dependent 26 
proteolysis 10. However, a sort of hierarchy appears to exist between these two processes, since a 27 
parallel study shows that autophagic degradation induced by starvation or FoxO3 overexpression 28 
is sufficient to determine muscle depletion even if the ubiquitin-proteasome degradation is 29 
blocked using pharmacological or genetic approaches 11. 30 
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As for cancer cachexia, results obtained on muscles isolated from cachectic animals led to 1 
rule out a substantial role for lysosomes in the overall protein degradation 12. On the other hand, 2 
an elevation of total lysosomal protease activity has been observed in the skeletal muscle and liver 3 
of tumor-bearing rats 13, and muscle depletion could be prevented by treatment of tumor hosts 4 
with leupeptin, an inhibitor of cysteine proteases such as cathepsins B, H, and L  14. Finally, 5 
increased levels of cathepsin L mRNA have been reported in the skeletal muscle of septic or 6 
tumor-bearing rats, while cathepsin B gene expression has been shown to be enhanced in muscle 7 
biopsies obtained from lung cancer patients 15, 16. 8 
 The present work has been aimed to investigate the relevance of autophagy to the 9 
pathogenesis of skeletal muscle wasting in cancer cachexia. In this regard, only recently few and 10 
scanty observations suggested that autophagy can be activated in the muscle of animals bearing 11 
the Lewis lung carcinoma or the colon 26 tumor 8, 17-19. However, a comprehensive analysis of the 12 
activation of the autophagic-lysosomal proteolytic pathway, including the evaluation of 13 
autophagic flux, in cancer hosts is still lacking. The present study fills this gap.  Not only, cancer-14 
induced muscle wasting has been compared, in terms of activation of autophagy, with that 15 
occurring in other experimental conditions such as glucocorticoid-induced atrophy and aging. On 16 
this line, previous data reported that autophagy significantly contributes to muscle wasting in 17 
different experimental conditions, such as denervation, starvation and sepsis 10, 20. However, while 18 
some of the mechanisms underlying glucocorticoid-induced atrophy have already been described 19 
21-23, only two reports have provided little evidence, also indirect, about the involvement of 20 
autophagy 24, 25. The present study, extensively investigating the effects of glucocorticoid 21 
administration on the activation of muscle autophagy, clarifies this point. As for aging, only a 22 
couple of reports 26, 27 analyzed the modulations of muscle autophagy. The present study extends 23 
such findings providing a panel of  autophagy markers in the aged muscle at protein levels, and 24 
comparing their changes with those occurring in aged animals exposed to 40% calorie restriction. 25 
The results show that autophagic-lysosomal degradation is induced in three different 26 
models of cancer-associated muscle atrophy as well as in glucocorticoid-treated animals, 27 
suggesting this proteolytic system as a possible target of therapeutic strategies. 28 
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MATERIALS AND METHODS 1 
All materials were supplied by Sigma-Aldrich, unless differently specified. 2 
Animals and experimental design 3 
Experimental animals were cared for in compliance with the Italian Ministry of Health 4 
Guidelines (n° 86609 EEC, permit number 106/2007-B) and the Policy on Humane Care and Use of 5 
Laboratory Animals (NIH 1996). The experimental protocol was approved by the Bioethical 6 
Committee of the University of Torino. Male Wistar rats weighing about 150 g,  Balb-c and 7 
C57/BL6 mice weighing about 20 g were obtained from Charles River Laboratories, and maintained 8 
on a regular dark-light cycle (light from 08:00 to 20:00), with free access to food and water during 9 
the whole experimental period. Tumor-bearing rats (n = 8) received an intraperitoneal (i.p.) 10 
inoculum of Yoshida AH-130 ascites hepatoma cells (~108 cells/rat; provided many years ago by 11 
Prof. M. Del Monte, University of Milano, Italy, and maintained in our lab by weekly i.p. 12 
transplantation), while tumor-bearing mice (n = 8) were inoculated subcutaneously dorsally with 13 
5x105 C26 carcinoma cells (kindly provided by Prof. M.P. Colombo, IRCCS National Cancer 14 
Institute, Milano, Italy) or intramuscularly with 5x105 Lewis Lung carcinoma cells (ATCC, USA). 15 
Both C26 and LLC cells were expanded in vitro (50.000 cm2, Dulbecco’s Modified Eagle’s Medium 16 
(DMEM) supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml 17 
sodium pyruvate, 2 mM L-glutamine,  maintained at 37°C in a humidified atmosphere of 5% CO2 in 18 
air), detached with trypsin, re-suspended in sterile saline and subsequently implanted in the 19 
animals at the concentrations indicated above. Rats or mice inoculated with vehicle (saline) served 20 
as controls (n = 6). In another set of experiments, animals were randomized and divided into four 21 
groups, namely controls (C, n = 6) and C26 (n = 8), treated or not with insulin (INS). INS groups 22 
received daily i.p. injections of insulin (1,5 IU/kg b.w.) during the whole experimental period. For 23 
‘autophagic flux’ experiments controls (C, n = 6) and C26 (n = 6) mice were either administered 24 
colchicine 0,4 mg/kg/day or vehicle for two days before sacrifice (both day 11 and day 14 of tumor 25 
growth). Dexamethasone (Dexa) was administered i.p. daily for 7 days to 6 week old Balb-c mice 26 
(n=8) at the dose of 1 mg/kg. Vehicle (saline containing 5% ethanol)-treated mice served as 27 
controls (n=6). Animal weight and food intake were recorded daily. Tumor-bearing rats and mice 28 
were sacrificed under anesthesia 7 and 14 days after tumor transplantation, respectively. Several 29 
muscles and organs were rapidly excised, weighed, frozen in isopentane cooled with liquid 30 
nitrogen and stored at –80°C. As for calorie restriction (CR), 6 month-old rats were either fed ad-31 
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libitum (AL) or given 60% (w/w; 40% CR) of the food consumed by AL animals until 24 months of 1 
age. As for the in vivo TNF administration, C57/BL6 mice weighing about 20 g received an 2 
intramuscular injection of TNF as previously reported (40µg/kg body weight 28, 29) in the right 3 
gastrocnemius and were sacrificed after 12h. Saline treated mice in place of using the 4 
contralateral muscle served as control in order to exclude TNF-dependent systemic effects.  5 
Insulin Tolerance Test  6 
 Control, C26 and C26 INS-treated mice at day 11 of tumor growth were challenged with 7 
insulin (1,5 IU/kg b.w., i.p.). A blood drop was collected by saphenous vein puncture before, 15,  8 
and 45 min. after insulin administration and glycemia was measured using the Glucocard G-sensor 9 
strips and apparatus (Menarini Diagnostics). Glycemia was also assessed before sacrifice collecting 10 
the blood by cardiac puncture from anesthetized animals in order to assess the relationship 11 
between glycemia and body weight changes. Correlation was calculated according to Pearson’s. 12 
Cell cultures 13 
Murine C2C12 skeletal myoblasts (ATCC) were grown in high glucose DMEM supplemented 14 
with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml sodium pyruvate, 2 mM L-15 
glutamine, and maintained at 37°C in a humidified atmosphere of 5% CO2 in air. Differentiation 16 
was induced by shifting sub-confluent cultures to DMEM supplemented with 2% horse serum 17 
(differentiation medium; DM). At the same time, the cells were exposed to TNFα (100 ng/ml) or to 18 
INS (10ug/ml), or both, and collected after 48 h; untreated cells served as control. Such 19 
differentiation scheme was chosen after a preliminary screening of the TNFα-dependent 20 
autophagy induction in growing myoblasts, differentiating (2 days) or fully differentiated (6 days) 21 
myotubes. The differentiating cells showed the strongest autophagy alterations (data not shown) 22 
and were adopted for the following experiments. In a different set of experiments TNFα action 23 
was also tested at a lower dose (5 ng/ml) in fully differentiated myotubes. For ‘autophagic flux’ 24 
measurements, 200 nM Bafilomycin A1 was added 6 hours before the termination of the 25 
experiments, as previously reported30. As for the data showed in Figure S6, at the time of shifting 26 
sub-confluent cultures to differentiation medium, the cells were exposed to a stable IGF-1 27 
synthetic peptide (LONG-R3IGF-I, Sigma 85580C, 50 ng/ml) or to neutralizing anti-IGF-1 antibody 28 
(Sigma I8773), in the presence or in the absence of TNFα (100 ng/ml) and collected after 48 h; 29 
untreated cells served as control. 30 
Primary satellite cells 31 
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 Single muscle fibers with associated satellite cells were isolated from the tibialis anterior 1 
muscles after digestion with collagenase. Single myofibers were plated on matrigel-coated dishes 2 
in DMEM supplemented with 20% FBS, 10% horse serum, 0.5% chick embryo extract and 3 
penicillin-streptomycin. Three days later the medium was replaced with proliferation medium 4 
(DMEM 20% FBS, 10% horse serum, 1% chick embryo extract) to promote proliferation of 5 
detached cells (delaminated satellite cells). After 5 days (only satellite cells remain on the plate), 6 
the medium was replaced with differentiation medium (2% horse serum and 0.5% chick embryo 7 
extract in DMEM). 8 
Western blotting 9 
About 50 mg of gastrocnemius muscle were homogenized in 80 mM Tris-HCl, pH 6.8, 10 
containing 100 mM DTT, 70 mM SDS, and 1 mM glycerol, with freshly added protease and 11 
phosphatase inhibitor cocktails, kept on ice for 30 min, centrifuged at 15000 x g for 10 min at 4°C, 12 
and the supernatant collected. Protein concentration was assayed using BSA as working standard. 13 
C2C12 cells were lysed on RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP40,  0.25% Na-14 
deoxycholate, 1 mM PMSF) with freshly added protease and phosphatase inhibitor cocktails. Equal 15 
amounts of protein (30 µg) were heat-denaturated in sample-loading buffer (50 mM Tris-HCl, pH 16 
6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol), resolved by SDS-PAGE and 17 
transferred to nitrocellulose membranes (Bio-Rad). The filters were blocked with Tris-buffered 18 
saline (TBS) containing 0.05% Tween and 5% non-fat dry milk and then incubated overnight with 19 
antibodies directed against: Beclin1 (Sigma B6186), LC3B (Sigma L7583), p62 (BD Biosciences 20 
610832), p-Akt (Ser473; Cell Signaling Technology 9271), atrogin-1 (ECMbiosciences AP2041) and 21 
tubulin (Sigma T5168). Peroxidase-conjugated IgG (Bio-Rad) was used as secondary antibodies. 22 
Quantification of the bands was performed by densitometric analysis using a specific software 23 
(TotalLab, NonLinear Dynamics, Newcastle upon Tyne, UK).  24 
Reverse transcription-PCR 25 
Total RNA was obtained using the TriPure reagent (Roche) following manufacturer’s 26 
instructions. RNA concentration was determined fluorometrically using the Ribogreen reagent 27 
(Invitrogen). RNA integrity was checked by electrophoresis on 1.2% agarose gel, containing 28 
morpholino propane-sulfonic acid (MOPS) 0.02 M and 18% formaldehyde. Total mRNA was retro-29 
transcribed using the i-Script cDNA synthesis kit (Bio-Rad). Transcript levels were determined by 30 
real-time PCR using the SsoFast Evagreen Supermix and the MiniOpticon thermal cycler (Bio-Rad). 31 
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Primer sequences were as follows: Atrogin1 FW-agcgacctcagcagttactgc, RW-cttctggaatccaggatggc; 1 
Beclin1 FW-tgaatgaggatgacagtgagca, RW-cacctggttctccacactcttg; Cathepsin L FW-2 
gtggactgttctcacgctcaag, RW-tccgtccttcgcttcatagg; LC3B FW-cactgctctgtcttgtgtaggttg, RW-3 
tcgttgtgcctttattagtgcatc; p62 FW-cccagtgtcttggcattctt, RW-agggaaagcagaggaagctc; NBR1 FW-4 
ccccagattggtttacaagc, RW-tccaccgtttccttaaccac. 5 
Cathepsin enzymatic activity 6 
Cathepsin B+L activity was determined by evaluating the cleavage of a specific 7 
chromogenic substrate (see 50). 50 mg of gastrocnemius muscle were homogenized in 0,25 M 8 
sucrose, 25 mM Hepes pH 7.4, 2 mM EDTA, and then centrifuged at 2000 g for 5 min at 4 °C. The 9 
supernatant was collected and centrifuged at 70000 g for 30 min at 4 °C. The pellet was suspended 10 
in 0,1 M Na-acetate pH 5.5, 1 mM EDTA. Aliquots of 10 g protein were incubated for 60 min at 37 11 
°C in the presence of 100 µM substrate (Z-Phe-Arg-p-Nitroanilide, Enzo Life Sciences). The 12 
incubation buffer was 0,5 M Na-acetate pH 5.5, 5 mM DTT, 2,5 mM EDTA. Absorbance was read 13 
with a spectrophotometer at 410 nm (Perkin-Elmer) using free p-Nitroanilide as working standard. 14 
Immunofluorescence 15 
C2C12 monolayers were washed with PBS and fixed in acetone-methanol (1:1). Samples 16 
were then probed with the following primary antibodies: LC3B (Sigma L7543), p62 (BD Biosciences 17 
610832). Detection was performed using a FITC-conjugated rabbit IgG secondary antibody. Nuclei 18 
were stained with the Hoechst 33342 fluorochrome and the images captured in an epiilluminated 19 
fluorescence microscope (Axiovert 35, Zeiss). 20 
Data analysis and presentation 21 
All results were expressed as mean ± SD, with the exception of gene expression (mean ± 22 
SEM). Representative western blots show independent samples. Significance of the differences 23 
was evaluated by analysis of variance (ANOVA) followed by Tukey’s test. 24 
25 
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RESULTS 1 
- Autophagy is induced in C26-bearing mice 2 
The C26 colon carcinoma induces progressive loss of body and muscle weight (see 3 
Supplemental Figure S1A and S1B at http://ajp.amjpathol.org). Muscle expression of proteins 4 
accepted as markers of autophagy has been assessed in the gastrocnemius muscle at both days 11 5 
and 14 of tumor growth, representing initial and advanced stage of muscle wasting, respectively. 6 
Beclin-1, a main upstream regulator of autophagic sequestration 31, is markedly increased already 7 
at day 11, suggesting that autophagy activation is an early event in tumor-induced muscle 8 
depletion (Fig. 1A). Secondly, levels of microtubule-associated protein 1 light chain 3B isoform I 9 
(LC3B-I) do not change in tumor-bearing mice, while the lipidated form (LC3B-II), a reliable marker 10 
of autophagosome formation 30, is significantly elevated at both experimental time points (Fig. 11 
1A). Moreover, the levels of p62/SQSTM1 have been assayed as a measure of substrate 12 
sequestration into autophagosomes; p62, indeed, binds LC3 as well as substrates marked for 13 
degradation by ubiquitylation 30. Similarly to beclin-1 and LC3B-II, p62 accumulates at both 14 
experimental points (Fig. 1A), which could reflect either induction of autophagic sequestration or 15 
reduced autophagosome clearance 32. To clarify this point, a flux experiment was performed by 16 
treating both controls and C26 hosts with colchicine, a microtubule-destabilizing agent that 17 
interacts with tubulin 33. The results show that LC3B-II levels, already higher than in controls in the 18 
C26 hosts, further increase after colchicine administration (Fig. 1B), demonstrating that autophagy 19 
is indeed activated. The reduction of tubulin expression in colchicine-treated animals (Fig. 1B) vs. 20 
untreated mice likely reflects specific drug-induced degradation 34, demonstrating that the 21 
treatment protocol adopted leads to bioactive colchicine levels in the skeletal muscle. Despite the 22 
flux experiment was designed in order to achieve data for both days 11 and 14 of tumor growth, 23 
only the first time-point could be evaluated; indeed, tumor-bearing animals administered 24 
colchicine on days 12 and 13 did not reach day 14 and died before sacrifice.  25 
The possibility that also reduced autophagosome clearance might occur in the present 26 
experimental setting cannot be discarded, however. A gene study shows that p62 transcript is 27 
increased at day 14 of tumor growth (Fig. 2A), while the enzymatic activity of lysosomal cathepsins 28 
is reduced at day 14, though not at day 11 (Fig. 2B), suggesting that p62 accumulation may result 29 
from transcriptional induction and, possibly, reduced degradation. The gene study also gives 30 
evidence for increased levels of mRNAs coding for atrogin-1, cathepsin L, LC3B and NBR1, a 31 
 10 
 
protein with functional similarity to p62 (Fig. 2A), further supporting the occurrence of a sustained 1 
induction of autophagy. Notably, autophagy induction in C26-bearing mice is not a feature specific 2 
for the skeletal muscle, being also detectable in the liver, wherein the pattern of LC3B and p62 3 
expression is comparable to that observed in the gastrocnemius (see Supplemental Figure S2A at 4 
http://ajp.amjpathol.org). 5 
- Autophagy is not a specific feature of the C26 hosts 6 
To assess if the enhanced autophagic degradation is peculiar to C26-bearing mice or also 7 
occurs in other experimental models of cancer cachexia, autophagic markers have been evaluated 8 
in the gastrocnemius muscle of rats bearing the Yoshida AH-130 hepatoma or of mice transplanted 9 
with the Lewis lung carcinoma (LLC). As for the former, muscle depletion induced by 7 days of 10 
tumor growth (Fig. 3A) is associated with both increased LC3B lipidation (LC3B-II) and p62 11 
accumulation, while no changes in beclin-1 levels occur (Fig. 3B). On the other side, muscle 12 
wasting in LLC hosts (Fig. 3C) is characterized by up-regulation of beclin-1 and p62 (Fig. 3D).  13 
These observations indicate that, though with different pattern, autophagy is activated in all 14 
the experimental models of cancer cachexia analyzed. In this regard, these results provide the first 15 
comprehensive approach to the contribution of autophagy to the pathogenesis of skeletal muscle 16 
wasting in cancer cachexia, confirming but significantly extending previous observations (see 17 
Introduction and Discussion). In addition, these result support the idea that a single marker is not 18 
sufficient to depict the state of activation of the autophagic-lysosomal degradative system 30. 19 
- Activation of autophagy in cancer-unrelated muscle wasting 20 
To investigate whether the modulations of autophagy in cancer-related muscle atrophy are 21 
comparable to those observed in other conditions associated with muscle wasting, autophagic 22 
markers were analyzed in dexamethasone (Dexa)-induced muscle atrophy and in aging-related 23 
sarcopenia. 24 
Dexamethasone  Mice received daily i.p. injections of Dexa, a synthetic glucocorticoid whose 25 
catabolic action has been thoroughly investigated 23. Body and muscle weight  loss induced by 26 
Dexa administration (7 days; Fig. 4A) are associated with increased expression of beclin-1 and both 27 
LC3B isoforms, while p62 virtually disappears (Fig. 4B). The different pattern of p62 expression in 28 
Dexa-treated mice compared to that observed in tumor-bearing animals is associated with lack of 29 
p62 transcriptional induction (Fig. 4C) as well as with normal cathepsin enzymatic activity (Fig. 4D). 30 
The gene study also shows an increased expression of atrogin-1, cathepsin L and NBR1 (Fig. 4C). 31 
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These observations are in line with previous data reporting that autophagy significantly 1 
contributes to muscle wasting in different experimental conditions, such as denervation, 2 
starvation and sepsis 10, 20. Not only, while providing a panel of  autophagy markers (at both gene 3 
and protein levels), the present results show that an efficient autophagosome clearance is 4 
achieved in the muscle of glucocorticoid-treated animals, as inferred by the markedly reduced p62 5 
levels.   6 
Aging  Both cancer and glucocorticoids induce muscle depletion in the short period (7-14 days, 7 
depending on the model), and can thus be considered as ‘acute’ wasting conditions. On the 8 
contrary, sarcopenia associated with aging is a chronic state and the underlying mechanisms could 9 
be different. To test the relevance of autophagy to sarcopenia, the same markers reported above 10 
have been measured in aged mice and rats. In 22 month old mice both beclin-1 and LC3B-I protein 11 
levels fall, while p62 markedly accumulates in comparison with 3 month old mice (Fig. 5A), 12 
suggesting a reduced autophagic degradation. As for the rats, the comparison between 6 and 24 13 
month old animals shows the accumulation of p62 (Fig. 5B). In the attempt to stimulate the 14 
autophagic flux, rats have been submitted to 40% calorie restriction, an anti-aging strategy 15 
previously shown to activate liver autophagy 35. In the present conditions, calorie restriction 16 
reduces both LC3B-II and p62 levels in the skeletal muscle, likely releasing the autophagy blockade 17 
(Fig. 5B).  18 
- Autophagy in cancer-induced muscle atrophy is only partially modulated by insulin 19 
Autophagy is mainly regulated by the PI3K/Akt/mTOR (mammalian Target of rapamycin) 20 
pathway and previous data showed that insulin administration effectively prevented muscle 21 
protein hypercatabolism in rats bearing the AH-130 hepatoma 14. To test if insulin effectiveness in 22 
preventing muscle wasting could rely on down-regulation of the autophagic degradation, the 23 
hormone was administered to C26-bearing mice, the model system where autophagy appears 24 
more marked. In contrast with the results previously obtained in the AH-130 hosts 14, insulin 25 
administration does not attenuate cachexia in the C26 hosts (Fig. 6A). Beclin-1 and p62 protein 26 
levels in insulin-treated tumor hosts are reduced in comparison to the untreated animals, but 27 
remain significantly higher than in controls, demonstrating that insulin inhibition of autophagy is 28 
far from being complete (Fig. 6B). Such a pattern is not peculiar to the skeletal muscle, since 29 
comparable results can be observed in the liver (see Supplemental Figure S2B at 30 
http://ajp.amjpathol.org). The gene study analysis shows that atrogin-1, beclin-1 and p62 31 
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transcripts are reduced by insulin, while cathepsin L and LC3B are even increased (Fig. 6C). The 1 
partial restoration of physiological autophagy exerted by insulin could reflect a condition of mild 2 
resistance to this hormone. In this regard, a study reported in the literature suggests that muscle 3 
wasting in C26 hosts is associated with insulin resistance 17. To clarify this point, an insulin 4 
tolerance test has been performed. The results show that both control and tumor-bearing animals, 5 
either treated  with insulin or not, respond comparably to insulin challenge, thus excluding the 6 
occurrence of insulin resistance (see Supplemental Figure S3B at http://ajp.amjpathol.org). In 7 
addition, the direct correlation existing between basal glycemia and body weight changes over the 8 
experimental period (see Supplemental Figure S3C at http://ajp.amjpathol.org), suggests that, at 9 
least in this experimental setting, hypoglycemia rather than insulin resistance contributes to the 10 
loss of body weight.  11 
- TNFα directly stimulates autophagic degradation in skeletal muscle cell cultures.  12 
Muscle wasting in cancer cachexia is largely mediated by proinflammatory cytokines. Indeed, 13 
protein hypercatabolism can be partially reversed by treating rats bearing the AH-130 hepatoma 14 
with anti-TNFα antibodies or with pentoxifylline, an inhibitor of TNFα synthesis 36, 37. We examined 15 
whether TNFα has the ability to directly activate the autophagic process in differentiating C2C12 16 
myocytes cultured in the presence of the cytokine for 48 hours. Similarly to a previous study 17 
obtained with the cytokine TWEAK (TNF-like weak inducer of apoptosis)38, TNFα causes a 18 
reduction of Akt phosphorylation (Fig. 7A). This observation seems in contrast with previous data 19 
showing increased levels of phosphorylated Akt in TNFα-treated C2C12 myotubes 39; the 20 
discrepancy may well result from the fact that the experiments here shown were performed on 21 
differentiating C2C12 myocytes (see Materials and Methods). The reduced levels of active Akt are 22 
associated with beclin-1 induction and LC3B-II accumulation (Fig. 7A), in the absence of significant 23 
changes of atrogin-1 expression (C = 0.55±0.15, TNF = 0.39±0.15, a. u., n = 3). Activation of 24 
autophagy is also suggested by the increased p62 (Fig. 7B) and dotted LC3B staining (C = 4 ± 2, TNF 25 
= 41 ± 9, cells with more than 10 puncta/60 nuclei, n = 3, p = 0.0024; Fig. 8B). A comparable 26 
pattern can be observed also in primary satellite cells exposed to TNFα (see Supplemental Figure 27 
S4A at http://ajp.amjpathol.org), as well as in C2C12 myotubes exposed to low TNFα 28 
concentrations (5 ng/ml; see Supplemental Figure S4B at http://ajp.amjpathol.org). Finally, 29 
‘autophagic flux’ was evaluated by incubating C2C12 cultures with bafilomycin A1, a drug able to 30 
inhibit the vacuolar H+-ATPase, resulting in reduced acidification and, therefore, lysosomal-31 
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dependent degradation of the autophagosome cargo 33. The results show that LC3B-II levels in 1 
bafilomycin A1-treated cells markedly increase with respect to controls. When cultures are 2 
exposed to TNFα and bafilomycin A1, LC3B-II levels are significantly higher than those measured in 3 
cells treated with bafilomycin A1 alone (Fig. 8A, see Supplemental Figure S4B at 4 
http://ajp.amjpathol.org). This observation suggests that the rate of LC3B-II formation is increased 5 
by the cytokine (see 40). Conversely, LC3B-II levels in C2C12 cultures treated with TNFα alone (100 6 
ng/ml, Fig. 8A) are not different from those detected in cells exposed to TNFα and bafilomycin A1. 7 
Such an observation would suggest that TNFα inhibits autophagosome degradation rather than 8 
enhancing their formation. However, lysosomal proteolysis should be completely blocked by 9 
bafilomycin; on this line, LC3B-II increase over bafilomycin-induced levels should result from 10 
enhanced autophagosome formation 40. This conclusion is strengthened by the results obtained on 11 
C2C12 myotubes exposed to  TNFα 5 ng/ml (Fig. S4B). In this regard, the results obtained on C2C12 12 
cells are on the same line of those reported for the muscle of the C26 hosts, where both inhibition 13 
of autophagosome degradation and increased sequestration are likely to occur. To ascertain if 14 
autophagy can be activated by TNFα also in vivo, healthy mice received an intramuscular injection 15 
of this cytokine (40µg/kg body weight 28, 29) and were sacrificed 12 h later. Figure S5 (available at 16 
http://ajp.amjpathol.org) shows that LC3B-II levels are increased in TNFα-treated muscles in 17 
comparison to the muscle of control mice, the more so when the animals also received colchicine, 18 
indicating the enhancement of autophagic flux. 19 
The data reported above indicate that exposure of muscle cell cultures to TNFα results in 20 
upregulation of autophagy. To clarify if this effect is responsive to anabolic regulation,  C2C12 cells 21 
were cotreated with TNFα and insulin. As expected, the results show that insulin alone increases 22 
Akt phosphorylation (C = 0.21±0.05, INS = 0.31±0.03, a. u., n = 3, p<0.05) and reduces both 23 
atrogin-1 expression (C = 0.55±0.15, INS = 0.28±0.05, a. u., n = 3, p<0.05) and LC3B-II levels (Fig. 24 
7A). These observations, together with the enhanced immunostaining for p62 (Fig. 7B), suggest 25 
that basal autophagy is inhibited. When insulin is coupled to TNFα, no significant changes could be 26 
observed as for atrogin-1 expression (INS = 0.28±0.05, INS+TNF = 0.24±0.06, a. u., n = 3) and Akt 27 
phosphorylation (INS = 0.31±0.03, INS+TNF = 0.18±0.10, a. u., n = 3; Fig. 7A), although a tendency 28 
to reduction is apparent.  Despite insulin exposure, both TNFα-induced beclin-1 and LC3B-II 29 
increase remain detectable (Fig. 7A). In the presence of bafilomycin A1, insulin results in LC3B-II 30 
accumulation lower than in cells exposed to the lysosomal inhibitor alone (Fig. 8B). However, in 31 
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insulin and bafilomicyn A1 treated cultures, LC3B-II levels in the presence of TNFα are higher than 1 
those observed in the absence of the cytokine, although they do not reach those obtained in cells 2 
exposed to bafilomycin A1 alone (Fig. 8B). Such observation suggests that insulin reduces basal 3 
autophagic flux but is unable to completely prevent the activation induced by TNFα exposure. This 4 
hypothesis is confirmed by LC3B immunostaining (INS = 5 ± 1, TNF+INS = 60 ± 9, cells with more 5 
than 10 puncta/60 nuclei, n = 3, p = 0.00025; Fig. 7B). Similar results have been obtained by 6 
treating the cells with recombinant stable IGF1, while treatment with an IGF1 neutralizing 7 
antibody is sufficient to activate autophagy, although to levels lower than those attained by TNFα 8 
(see Supplemental Figure S6A and S6B at http://ajp.amjpathol.org). 9 
10 
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DISCUSSION 1 
The present study demonstrates that muscle wasting in three different experimental 2 
models of cancer cachexia is associated with increased autophagy, as evaluated by analyzing three 3 
among the most representative markers of this degradative pathway: beclin-1 as an indicator of 4 
autophagy induction, LC3B conversion to the lipidated form to measure  autophagosome 5 
abundance and p62/SQSTM1 as a marker of substrate sequestration and eventual degradation 6 
(see Results). The analysis of these proteins gives an approximate estimate of the autophagic flux, 7 
i.e. the extent of protein sequestration and subsequent degradation into lysosomes. To further 8 
strengthen the data, autophagic flux was measured by treating C26 hosts with colchicine (see 33). 9 
Although the markers of autophagy mentioned above do not strictly share the same pattern of 10 
expression in the cachexia models used in the present study, the net result is that in all of them an 11 
increase of autophagic degradation is likely to occur. This observation represents an important 12 
new finding. Indeed, while muscle wasting in cancer cachexia is considered to depend mainly on 13 
hyperactivation  of proteasomal degradation 2, 41-44, only recently beclin-1 and LC3B induction was 14 
shown in LLC-bearing mice 8, while Bnip3 overexpression or increased LC3B-II levels in the C26 15 
hosts were previously reported 17, 18. Finally, autophagy was proposed to contribute to C26-16 
induced cardiac atrophy 19. 17 
To the best of our knowledge,  the data shown in the present study represent the most 18 
comprehensive analysis actually available showing how the autophagic system is poised towards 19 
activation in the skeletal muscle of the C26-bearing mice. Similar conclusions can be drawn from 20 
results obtained in rats bearing the AH-130 Yoshida hepatoma, where hyperactivation of muscle 21 
lysosomal proteases was already shown by Tessitore et al. 13, and in mice implanted with the LLC 22 
tumor, these latter confirming but extending what previously reported by Paul and coworkers 8. 23 
These results highlight the relevance of autophagy to cancer-induced muscle wasting, the more so 24 
when considering that not only the upstream signals that activate protein breakdown are able to 25 
coordinate both autophagy and proteasome induction 45, 46, but also that typical proteasome 26 
substrates (e.g. ubiquitylated proteins) can be alternatively degraded through the acidic vacuolar 27 
proteolysis 47. 28 
A careful analysis of the results here presented suggests that, despite autophagy is 29 
activated in both cancer cachexia and dexametasone-induced muscle atrophy, but not in 30 
sarcopenic muscles, different mechanisms are operating in the specific experimental conditions. 31 
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As for cancer cachexia, all the markers of autophagy are up-regulated in the C26 hosts. Particularly 1 
interesting in this regard is the marked accumulation of p62, that contrasts with the observation 2 
that autophagic flux  is clearly enhanced, at least in d11 C26 hosts (see Fig. 1B). Such increased p62 3 
levels could reflect a transcriptional induction, as reported in desmin-related cardiomyopathy48. 4 
Consistently, p62 gene expression is markedly increased in the muscle of the C26 hosts. 5 
Autophagic flux measurement was not possible in day 14 C26 hosts, since colchicine-treated 6 
animals died before sacrifice, suggesting that autophagy inhibition negatively impinges on survival 7 
when the metabolic homeostasis is markedly compromised.  8 
Despite the induction of autophagy, muscle lysosomal cathepsin activities are reduced in 9 
day 14 C26 bearers, a finding that may reflect selective disturbances in lysosomal function, such as 10 
lysosomal enzyme mistargeting 49. In this regard, the possibility that during tumor growth muscle 11 
protein degradation relies initially on the lysosomal system and only subsequently on other 12 
proteolytic pathways cannot be excluded. Consistently, lysosomal protease activity is reduced only 13 
in day 14 C26 hosts (advanced cachexia), in parallel with both increased atrogin-1 mRNA levels and 14 
calpastatin degradation, this latter being a marker of calpain hyperactivation (unpublished data).  15 
As for dexamethasone-induced atrophy, the results show that both beclin-1 and LC3B-II 16 
increase, while p62 virtually disappears, indicating that substrates sequestered into 17 
autophagosomes are readily degraded by lysosomes. The lack of p62 accumulation in the skeletal 18 
muscle of dexamethasone-treated mice is associated with unchanged levels of p62 transcript. In 19 
addition, this observation suggests that even if rapid muscle atrophy observed in both tumor 20 
bearers and glucocorticoid-treated mice is characterized by autophagic degradation, the molecular 21 
signals involved are different and may require distinct therapeutic approaches.  22 
 Finally, autophagic degradation is reduced in the skeletal muscle of aged animals while is 23 
reactivated by CR, consistently with recent data 26. Reduced muscle mass occurs in both aging and 24 
CR 50, however the pattern of the autophagic markers is quite different. Indeed, while in aged 25 
animals both beclin-1 and LC3B-II are comparable, or even reduced vs. young individuals, p62 26 
levels are markedly increased, likely because autophagy is not activated, and waste substrates 27 
accumulate. While impairment of autophagic degradation during aging is a well known event in 28 
the liver, the present observations represent a new finding, since very few data are actually 29 
available as for the skeletal muscle 26. In this regard, abnormal mitochondria and sarcomere 30 
disorganization in aged skeletal muscle likely results from impaired autophagy. Consistently, 31 
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muscle-specific deletion of Atg7, a crucial autophagy gene, leads to phenotypic alterations 1 
resembling sarcopenia 51. As for CR, it is associated with p62 levels that are still increased with 2 
respect to young animals, but markedly reduced in comparison to aged rats, suggesting a partial 3 
restoration of the autophagic flux. These observations are in agreement with a previous report by 4 
Wohlgemuth et al.26, showing that 8% calorie restriction was able to partially restore the reduced 5 
expression of autophagic markers in aged rats.  6 
In the C26 host, energy deficit, whose occurrence is suggested by  the correlation between 7 
hypoglycemia and body weight loss as well as by mitochondrial damage (Penna et al., unpublished 8 
data), is a possible trigger of autophagy, not only in the skeletal muscle, but also in the liver 52. 9 
Such a speculation would fit with the recently proposed model of “battery-operated tumor 10 
growth”, where autophagic degradation is suggested to start in the tumor stroma and then to 11 
spread systemically in order to provide a continuous energy transfer from the host to the tumor 53. 12 
The onset of cancer cachexia is also associated with a proinflammatory environment 54, 55. 13 
In this regard, anti-TNFα strategies have been shown to effectively prevent the hyperactivation of 14 
proteasomal degradation in the AH-130 hosts  36, 37. Recent data show that TRAF6  induces the 15 
expression of muscle-specific E3 ubiquitin ligases and autophagy-related molecules in the skeletal 16 
muscle upon denervation and in LLC-bearing mice 8. Moreover, TWEAK has been reported to 17 
induce the activation of both autophagy and proteasome in C2C12 myotubes 56. The results 18 
obtained in the present study show that TNFα directly stimulates autophagic degradation in both 19 
C2C12 and isolated murine satellite cells, suggesting another possible trigger of autophagy in 20 
cancer cachexia.  21 
A relevant issue raised in the present work concerns the observation that TNFα exposure in 22 
vitro, as well as tumor growth in vivo, partially overcome the well known insulin/IGF-1 ability to 23 
down-regulate autophagy. These results could explain the virtual lack of effect of IGF-1/insulin-24 
based strategies in preventing cancer-induced muscle wasting (57, 58; present work). In this regard, 25 
a quite recent study reported that increased IGF-1 receptor engagement in the skeletal muscle 26 
results in rapid IRS-1 phosphorylation and proteasome-dependent degradation 59. On the contrary, 27 
IGF-1 overexpression effectively prevents glucocorticoid-induced muscle atrophy as well as the 28 
sarcopenia of aging 22, 57, although no information regarding the effect on autophagy in these 29 
model systems are actually available. 30 
Conclusions 31 
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The results reported in the present study show that autophagy contributes to generate 1 
muscle atrophy in cancer cachexia as well as in dexamethasone-treated animals, although the 2 
underlying mechanisms in the two conditions are likely different. By contrast, sarcopenia of aging, 3 
a slow but progressive physiological loss of muscle mass, does not seem to depend on autophagy. 4 
These results further support the idea that the final event, e.g. muscle wasting, likely derives from 5 
the combination of different mechanisms; in this regard, autophagy participates to variable extent 6 
to the complicated network that leads to the loss of muscle mass. Finally, catabolic stimuli such as 7 
the presence of a tumor or, more specifically,  proinflammatory cytokines, cannot be fully 8 
antagonized, at least in terms of autophagic degradation, by insulin, one of the most powerful 9 
inhibitors of autophagy. These results are particularly intriguing, and could suggest that activation 10 
of autophagy in these model systems is so enforced that cannot be circumvented by simple 11 
inhibitor-based strategies. 12 
13 
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FIGURE LEGENDS  1 
Figure 1. Densitometric analysis and representative patterns of expression of autophagy-related 2 
proteins in the GSN muscle of C and C26 bearers at 11 or 14 days after tumor transplantation (A). 3 
Densitometric analysis and representative patterns of expression of LC3B protein in the 4 
gastrocnemius of C and C26 hosts at day 11 of tumor growth either untreated or treated with 5 
colchicine (Col; B). Data (mean ± SD) are expressed as percentages of C. Significance of the 6 
differences: *p<0.05 vs C, **p<0.01 vs C,***p<0.001 vs C, ## p<0.01 vs Col, $$p<0.01 vs C26. 7 
Figure 2. Expression of genes involved in atrophy (A)  and cathepsin B+L activity (B) in the GSN of C 8 
and C26 hosts at day 14 and 11 of tumor growth. Data (mean ± SD) are percentages of C. As for 9 
gene expression results are expressed as mean ± SEM. Significance of the differences vs C: 10 
*p<0.05, **p<0.01, ***p<0.001.   11 
Figure 3. Gastrocnemius muscle mass and expression of autophagy-related proteins in GSN of AH-12 
130 (A, B) or LLC tumor-bearing animals (C, D).  Data (mean ± SD) are expressed as percentages of 13 
C. Significance of the differences vs C: *p<0.05, **p<0.01, ***p<0.001. 14 
Figure 4. Loss of body weight and skeletal muscle mass in dexamethasone-treated mice (A; GSN = 15 
gastrocnemius, TIB = tibialis). Densitometric analysis and representative patterns of expression of 16 
autophagy-related proteins in the GSN muscle of C and DEXA-treated mice (B). Expression of genes 17 
involved in atrophy (C) and cathepsin B+L activity (D)  in the GSN of C and DEXA-treated mice. Data 18 
(mean ± SD), are percentages of C. As for gene expression results are expressed as mean ± SEM. 19 
Significance of the differences vs C: *p<0.05, **p<0.01, ***p<0.001.  20 
Figure 5.  Densitometric analysis and representative patterns of expression of autophagy-related 21 
proteins in the gastrocnemius (GSN) of 3 and 22 month old mice (A) and 6 or 24 months old rats 22 
(B), fed ad libitum (AL) or  with 40% calorie restriction (CR). Data (mean ± SD), are percentages of 23 
C. Significance of the differences vs C: *p<0.05, **p<0.01, ***p<0.001; vs AL24: $ p<0,05. 24 
Figure 6. Loss of body weight and skeletal muscle mass in insulin-treated (1,5 IU/kg b.w.) animals 25 
(A; GSN = gastrocnemius, TIB = tibialis). Densitometric analysis and representative patterns of 26 
expression of autophagy-related proteins in the GSN muscle of C and C26 hosts, either treated or 27 
untreated with insulin (B). Expression of genes involved in atrophy in the GSN of C, C26 and INS-28 
treated C26 hosts (C). Data (mean ± SD), are percentages of C. As for gene expression, results are 29 
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expressed as mean ± SEM. Significance of the differences vs C: *p<0.05, ***p<0.001; vs C26 1 
$p<0.05, $$p<0.01.  2 
Figure 7. C2C12 myotubes (2 day differentiation) treated for 48 h with TNFα, in the presence or in 3 
the absence of INS. Densitometric analysis and representative patterns of expression of autophagy 4 
related proteins and of phospho-Akt (A). Data (mean ± SD; n=3) are expressed as percentages of 5 
controls. Significance of the differences: *p<0.05 vs C, **p<0.01 vs C; § p<0.05 vs TNFα. (B)  p62 6 
and LC3B immunostaining (green: p62 or LC3B-II; blue: HOECHST).  7 
Figure 8.  Densitometric analysis of expression of autophagy related proteins in C2C12 cells 8 
cultured in the presence or in the absence of bafilomycin A1 (BAF; A) and/or insulin (B). Data 9 
(mean ± SD; n=3) are expressed as percentages of controls. Significance of the differences: 10 
*p<0.05 vs C, **p<0.01 vs C; #p<0,05 vs BAF; $ p<0.05 vs BAF INS.  11 
SUPPLEMENTAL FIGURE LEGENDS  12 
Figure S1. Loss of body (A) and skeletal muscle weight (B; GSN = gastrocnemius, TIB = tibialis) in 13 
Controls and C26 hosts (C=6, C26=8) at day 11 and 14 of tumor growth.  14 
Figure S2. Densitometric analysis and representative patterns of expression of autophagy-related 15 
proteins in the liver of C and C26 hosts (A), or C, C26 bearers and INS-treated C26 hosts (B) at day 16 
14 of tumor growth. Data (mean ± SD) are expressed as percentages of C. Significance of the 17 
differences vs C: *p<0.05, **p<0.01, ***p<0.001; vs C26: $$p<0.01. 18 
Figure S3. Daily food intake (A) and insulin tolerance test (B)  in C, C26 and INS-treated C26 hosts. 19 
Correlation between glycemia and Δ i.b.w. in C26 hosts, either untreated (r=0.693) or INS-treated 20 
(r=0.939; C).  21 
Figure S4. (A) LC3B immunostaining in primary cultures of tibialis-derived satellite cells untreated 22 
or treated for 48h with TNFα (100 ng/ml; green = LC3B, blue = HOECHST). (B) Densitometric 23 
analysis and representative patterns of expression of LC3B-I and LC3B-II in C2C12 myotubes 24 
exposed to 5 ng/ml TNFα. Significance of the differences: *p<0.05 vs C, **p<0.01 vs C, $p<0.05 vs 25 
TNFα. 26 
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Figure S5. Densitometric analysis and representative patterns of expression of LC3B-I and LC3B-II 1 
in the muscle of C and TNFα-treated mice, in the presence or in the absence of colchicine 2 
administration (see Materials and methods).  Significance of the differences vs C: *p<0.05, 3 
**p<0.01.  4 
Figure S6. (A)LC3B immunostaining  in C2C12 myotubes (2 day differentiation) untreated or 5 
treated for 48 h with TNFa (100ng/ml), in the presence or in the absence of IGF1 (50 ng/ml) or 6 
anti-IGF1 antibody (a-IGF1 = 2ug/ml). (B) Densitometric analysis and representative patterns of 7 
expression of LC3B and phospho-Akt. Data (mean ± SD; n=3) are expressed as percentages of C . 8 
Significance of the differences vs C: *p<0.05, **p<0.01.9 
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